PIPELINE
Venadaparib (IDX-1197) is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promote the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells. IDX-1197 is under clinical development targeting multiple solid tumors as a monotherapy (including maintenance) and for combination with other anti-cancer agents.
Main_DNA_Precision_Medicine.jpg

Development of Venadaparib, a novel, selective, and highly potent PARP inhibitor

Science_Oncology.jpg

A comparative preclinical study of PARP inhibitors demonstrates superb properties for Venadaparib